City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the U.S. with its National Medical Center named top 5 in the nation for…
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune…
Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, and Databricks, the Data and AI company, today announced a partnership to advance precision…
ForeSee Medical Inc., a leading AI-powered risk adjustment software company, and Vim, a cutting-edge provider enablement platform for healthcare, have announced a strategic partnership aimed at transforming the delivery of…
HistoSonics Completes Enrollment in HOPE4KIDNEY Trial for Non-Invasive Tumor Treatment HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient…
OS Therapies Inc. (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced it has submitted a request for Regenerative Medicine Advanced…
Aethera Biotech officially announced a strategic partnership with Chinese premium skincare brand Shang Renée, marking the latter as Aethera Biotech’s first collaborative partner in the Chinese market. This collaboration not…
Otsuka’s Sibeprenlimab Shows Significant Proteinuria Reduction in IgAN Phase 3 Trial Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka) today presented results from a pre-specified interim…
Simplify Healthcare, a recognized leader in enterprise software solutions for Payers, proudly announces that its flagship platform, Benefits1™.Medicare, played a key role once again in streamlining over 30% of Medicare Advantage (MA)…
MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer through immune…
GE HealthCare (Nasdaq: GEHC) today announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in…
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from the dose confirmation portion of the Phase 2/3 waveLINE-003 study evaluating zilovertamab vedotin…